Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

PRECOS Launches PUMA at AACR 2013

Published: Monday, April 08, 2013
Last Updated: Monday, April 08, 2013
Bookmark and Share
Company launches portfolio of techniques and models of acquired resistance to targeted agents and standards of care used in oncology.

Preclinical Oncology Services Limited (PRECOS) has launched PRECOS Unique Models of Acquired resistance (PUMA) at the AACR annual meeting (Washington DC, April 6th - 10th).

Derived from cell lines and proprietary PDX (Patient-Derived Xenograft) models, PUMA models provide a unique bespoke collection of clinically relevant and validated models of resistance, as well as the techniques and expertise to develop client specific models of acquired resistance to chemotherapeutics and targeted agents.

Such models are a major advancement for pharmaceutical and biotech companies running oncology R&D programmes and will enhance success rates during the critical phase of transitioning from pre-clinical to clinical evaluation of new drug candidates.

The first available examples of PUMA models are in specific lung cancer subsets where PRECOS has previously developed and characterized a focused panel of PDX lung cancer models derived directly from Caucasian patient tumour material - PRECOS’ unique model atlas LION (Lung In ONcology).

By repeatedly challenging relatively homogeneous cell line populations (CTX models) and heterogeneous tumours from PDX models across several passages, PRECOS is able to compare and contrast behaviour such as growth characteristics with gene expression and pathway analysis, response to chemotherapeutics and targeted agents.

It is also possible to assess the effect of varying treatment regimens and dosing strategies including drug holidays or combination therapies.

This allows panels of tumour subset specific models to be built which are able to mimic patients and their responses to treatment regimes in the clinic.

PRECOS is committed to further developing PUMA and is continuing to progress the techniques to provide customized services.

This will enable its clients to build models based on the characteristics of diverse cancer cell types which can offer insights for designing optimal treatment strategies around their pre-clinical candidates prior to product development and clinical trials.

“As oncology R&D progresses, there is an increasingly critical need for more clinically-relevant predictive pre-clinical models in order to overcome the high attrition rates of agents entering clinical trials,” said Dr Martin Page, Scientific Consultant, PRECOS.

Dr Page continued, “All new agents entering phase 1 clinical trials will be tested in cancer patients that have likely become resistant to a range of targeted and chemotherapeutic agents. PUMA is part of our PREdict platform, and offers PRECOS’ clients pre-clinical models that are authentic counterparts of the drug-resistant tumour subsets seen in the clinic, rather than drug-naive models. PRECOS’ latest portfolio offers specialist drug resistant pre-clinical models with responses of higher predictability with outcomes that can be seen during clinical testing.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Latest Advances in PDX Modelling for Oncology Drug Discovery
PRECOS' co-presentation with Crown Bioscience from Tumor Models Boston 2013 meeting available for download.
Friday, September 13, 2013
PRECOS Doubles Capacity and Appoints New Senior Scientific Staff to Accommodate Significant Growth
The company has expanded to accommodate existing and anticipated growth in line with its leadership in oncology drug discovery.
Tuesday, February 15, 2011
PRECOS Secures Multi Year Global Service Agreement with Leading Pharmaceutical Company
Preclinical Oncology Services Limited (PRECOS) has signed a significant service agreement with a leading global pharmaceutical company Janssen Pharmaceutica N.V. The contract will see PRECOS provide clinical tumour material, tumour model development, target validation and drug efficacy work to support Janssen’s oncology drug discovery, development and biomarker programmes.
Thursday, November 25, 2010
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Study Questions Presence in Blood of Heart-Healthy Molecules from Fish Oil Supplements
A new study from the Perelman School of Medicine at the University of Pennsylvania questions the relevance of fish oil-derived SPMs and their purported anti-inflammatory effects in humans.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Key Player in Diabetic Kidney Disease Revealed
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!